FDA accepts premarket approval application for DE-128 microshunt

The U.S. Food and Drug Administration has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review, according to a press release from Santen Pharmaceutical Co.

The microshunt is an investigational surgical glaucoma implant designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications.

Read the full press release here.  

Source: Santen Pharmaceutical Co., Ltd.